Targeted drug olaparib tested in breast cancer patients with DNA repair flaws

NCT ID NCT03344965

Ongoing Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests the drug olaparib in 114 people with metastatic breast cancer whose tumors have mutations in certain DNA repair genes (like BRCA1, BRCA2, ATM, PALB2, and others). Olaparib is a PARP inhibitor that may kill cancer cells by blocking their ability to fix damaged DNA. The study aims to see how many patients respond to the treatment and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Olaparib (a PARP inhibitor drug taken as tablets)

What this could lead to

If successful, this could provide a targeted treatment option for metastatic breast cancer patients with certain inherited or tumor-acquired DNA repair gene mutations.

What could go wrong

This is a mid-stage trial with a moderate number of participants. The drug may not shrink tumors or improve survival for all mutation types, and side effects like fatigue, nausea, or blood count changes are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm CHEK2-related cancer predisposition Fanconi anemia complementation group D1 invasive breast carcinoma PALB2-related cancer predisposition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATM GENE MUTATION BRIP1 GENE MUTATION CHEK2 GENE MUTATION INVASIVE BREAST CANCER METASTATIC BREAST CANCER NBN GENE MUTATION PALB2 GENE MUTATION RAD51 GENE MUTATION SOMATIC MUTATION BREAST CANCER (BRCA1) SOMATIC MUTATION BREAST CANCER (BRCA2)

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University

Durham, North Carolina, 27708, United States
Indiana University

Indianapolis, Indiana, 46202, United States
Johns Hopkins University

Baltimore, Maryland, 21218, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Cancer Center Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Cancer Center Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Cancer Center Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Cancer Center Westchester

East White Plains, New York, 10604, United States
UPMC Hillman Cancer Center - Erie

Erie, Pennsylvania, 16505, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of California, San Francisco

San Francisco, California, 94143, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh

Pittsburgh, Pennsylvania, 15260, United States
University of Washington Fred Hutchinson Cancer Care

Seattle, Washington, 98109, United States